The FDA’s landscape is shifting rapidly with leadership changes, staff reductions, and evolving policy priorities. This webinar will provide an overview of how these dynamics—along with Congressional oversight, budgetary restrictions, and policy function mergers—are affecting the agency’s operations and strategic direction. We’ll explore the anticipated reforms in drug review and approval, the integration of artificial intelligence, and the future of diversity in clinical trials and enhanced patient data use.

Join Maggie Alston and Rebecca Smith and Jeff Garbe of Milliman, and Alison Falb of Coral Health Advisors to understand what these changes mean for your organization and how to proactively respond.